• Harmonizing UK Biobank GWAS Data with DISGENET: Mapping Phecodes to UMLS CUIs

    April 23, 2025

    UK Biobank data is an invaluable resource for genetic research, containing genetic, lifestyle, and health information from half a million individuals. To leverage this wealth of data, DISGENET v25.1 features the integration of a dataset that provides genome-wide associations for Electronic Health Record (EHR)-derived phenotypes from White British participants in the UK Biobank (data available at PheWeb UKB-TOPMed). […]

  • DISGENET v25.1: What’s New?

    April 3, 2025

    Discover our biggest data expansion to date with DISGENET v25.1—your platform for deeper, more actionable disease-genomics insights to accelerate research and advance precision medicine. DISGENET version 25.1 includes: A Data Revolution to Power Your Discoveries In our latest release, we’re not just expanding the breadth of our data—we’re enhancing its depth to empower your research […]

  • DISGENET Version 24.4: What’s New?

    December 5, 2024

    DISGENET, the largest and most extensive gene-disease association network, has released version 24.4, which means new functions and features designed to support your genomics research. DISGENET version 24.4 includes: With these changes, we continue to provide the DISGENET community with reliable sources, accessible data, and actionable tools all within one single platform. Advanced Search The […]

  • DISGENET Version 24.3: What’s New?

    October 8, 2024

    DISGENET, the largest and most extensive gene-disease association network, has released version 24.3, featuring several new additions. DISGENET version 24.3 includes: With these enhancements, DISGENET continues to provide you with reliable sources, accessible data, and actionable tools to support your research all within one platform. The DISGENET AI Assistant We have released a beta version […]

  • Genetics In Drug Discovery: The Key To Clinical Trial Success?

    August 28, 2024

    By leveraging human genetics to identify drug targets with a proven link to disease mechanisms, the probability of clinical trial success greatly increases [1]. Only 10% of drugs that enter phase 1 clinical trials eventually make it to market [2], primarily due to issues related to efficacy or safety that arise later on. These frequent […]

  • DISGENET Academic License: Eligibility, Application & Free Access

    August 2, 2024

    DISGENET is the most extensive and reliable gene-disease association network, providing the latest and most relevant data in the field. It was created by MedBioinformatics. As an academic or not-for-profit researcher, you can access DISGENET’s core biomedical data at no cost. For deeper insights, we offer additional options utilizing state-of-the-art NLP technology. In this blog, we […]

  • DISGENET NLP for Drug Discovery

    How DISGENET Uses NLP To Accelerate Drug Development

    July 19, 2024

    With DISGENET, you can easily unlock new insights and greatly accelerate your drug development journey. Every year, more than 1 million papers enter PubMed in the biomedical field [1]. While medical knowledge doubles every 73 days and is increasing at an exponential rate with no evidence of slowing [2], drug discovery and development remain a […]

  • DISGENET logo

    DISGENET: The Next Chapter For Disease Genomics Research

    June 19, 2024

    From today, DisGeNET.org and DISGENET plus will become one unified platform found at disgenet.com. DisGeNET has become a cornerstone for bioinformatics research since starting in 2010. As a small team, we have dedicated 15 years to this valuable resource and we are committed to continuously improving the platform for you, our users. As you can […]